Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia

被引:29
作者
Valero, Lucie [1 ,2 ,3 ,4 ,5 ]
Alhareth, Khair [1 ,2 ,3 ,4 ]
Gil, Sophie [3 ,5 ,7 ]
Lecarpentier, Edouard [3 ,5 ]
Tsatsaris, Vassilis [3 ,5 ,6 ,7 ]
Mignet, Nathalie [1 ,2 ,3 ,4 ]
Fournier, Thierry [3 ,5 ,7 ]
Andrieux, Karine [1 ,2 ,3 ,4 ]
机构
[1] PSL Res Univ, Chim ParisTech, UTCBS, F-75005 Paris, France
[2] UTCBS, CNRS, UMR 8258, F-75006 Paris, France
[3] Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France
[4] UTCBS, INSERM, U 1022, F-75006 Paris, France
[5] INSERM, UMR S1139, Fac Pharm Paris, F-75006 Paris, France
[6] Hop Cochin, AP HP, F-75014 Paris, France
[7] Fondat PremUp, F-75006 Paris, France
关键词
TYROSINE KINASE-1; CANCER-DIAGNOSIS; PLACENTAL SFLT1; LIPOSOMES; PREGNANCY; CELL; FUTURE; MODEL; SYNCYTIOTROPHOBLAST; HYPERTENSION;
D O I
10.1016/j.drudis.2018.01.048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Preeclampsia is a serious pregnancy disorder characterized by the onset of high blood pressure and proteinuria. Although the understanding of the disease is increasing, it remains without treatment, other than the delivery of the baby and the placenta. This review sets out to discuss some new developments and strategies in the treatment of preeclampsia. We briefly review the current knowledge on the preeclamptic pathophysiology. We then examine the recent trends in preeclampsia treatment and, in particular, the tracks of potential therapeutic targets. Finally, we focus on the possibilities nanocarriers could offer in the management of preeclampsia. Indeed, nanocarriers could help to prevent transplacental passage and promote placental-specific drug delivery, thereby enhancing efficacy and improving safety. Tendencies are then drawn from the available studies on the optimal characteristics of a nanocarrier to deliver drugs to the placenta.
引用
收藏
页码:1099 / 1107
页数:9
相关论文
共 67 条
  • [1] Preeclampsia and the anti-angiogenic state
    Agarwal, Isha
    Karumanchi, S. Ananth
    [J]. PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2011, 1 (01) : 17 - 21
  • [2] A New Mouse Model to Explore Therapies for Preeclampsia
    Ahmed, Abdulwahab
    Singh, Jameel
    Khan, Ysodra
    Seshan, Surya V.
    Girardi, Guillermina
    [J]. PLOS ONE, 2010, 5 (10):
  • [3] How should we plan the future of nanomedicine for cancer diagnosis and therapy?
    Alhareth, Khair
    Sancey, Lucie
    Tsapis, Nicolas
    Mignet, Nathalie
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 532 (02) : 657 - 659
  • [4] Major Malformation Risk, Pregnancy Outcomes, and Neurodevelopmental Outcomes Associated With Metformin Use During Pregnancy
    Andrade, Chittaranjan
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (04) : E411 - E414
  • [5] Effect of surface charge of small unilamellar liposomes on uptake and transfer of carboxyfluorescein across the perfused human term placenta
    Bajoria, R
    Contractor, SF
    [J]. PEDIATRIC RESEARCH, 1997, 42 (04) : 520 - 527
  • [6] Effect of lipid composition of cationic SUV liposomes on materno-fetal transfer of warfarin across the perfused human term placenta
    Bajoria, R.
    Sooranna, S.
    Chatterjee, R.
    [J]. PLACENTA, 2013, 34 (12) : 1216 - 1222
  • [7] Bajoria R, 1997, HUM REPROD, V12, P1343
  • [8] Effect of the size of liposomes on the transfer and uptake of carboxyfluorescein by the perfused human term placenta
    Bajoria, R
    Contractor, SF
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (07) : 675 - 681
  • [9] Liposomal thyroxine: A noninvasive model for transplacental fetal therapy
    Bajoria, R
    Fisk, NM
    Contractor, SF
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (10) : 3271 - 3277
  • [10] Barzago MM, 1996, J PHARMACOL EXP THER, V277, P79